Aakash Desai: New insights in BRAFV600–mutated NSCLC
Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, shared an article on LinkedIn:
“New insights in BRAFV600–mutated NSCLC from Wiesweg et al. in JTO:
This real-world study compared first-line BRAF/MEK targeted therapy with chemo-immunotherapy and found:
- No significant difference in overall survival between the two strategies.
- Gender and PD-L1 status were key prognostic factors.
- Supports an individualized approach to treatment selection.
These findings underscore the importance of precision oncology—tailoring therapy based on patient-level tumor biology. Read the full study here.”
Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy.
Authors: Marcel Wiesweg, Ali Alaffas, Anna Rasokat, Felix Carl Saalfeld, Maximilian Rost, Christin Assmann, Franziska Herster, Moritz Hilbrandt, Frank Griesinger, Anna Kron, Julia Roeper, Franziska Glanemann, Cornelia Kropf-Sanchen, Martin Reck, Jonas Kulhavy, Albrecht Stenzinger, Jürgen Wolf, Martin Sebastian, Martin Schuler, Martin Wermke, Nikolaj Frost, Hans-Georg Kopp, Petros Christopoulos, Matthias Scheffler.
You can read the Full Article on Journal of Thoracic Oncology.
More posts featuring Aakash Desai.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023